171 related articles for article (PubMed ID: 9467035)
1. The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures.
Cameron R; Davies J; Adcock W; MacGregor A; Barford JP; Cossart Y; Harbour C
Biologicals; 1997 Dec; 25(4):391-401. PubMed ID: 9467035
[TBL] [Abstract][Full Text] [Related]
2. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
[TBL] [Abstract][Full Text] [Related]
3. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
4. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
5. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
6. Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin.
Adcock WL; MacGregor A; Davies JR; Hattarki M; Anderson DA; Goss NH
Biotechnol Appl Biochem; 1998 Oct; 28 ( Pt 2)():169-78. PubMed ID: 9756468
[TBL] [Abstract][Full Text] [Related]
7. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses.
Valdés R; Ibarra N; Ruibal I; Beldarraín A; Noa E; Herrera N; Alemán R; Padilla S; Garcia J; Pérez M; Morales R; Chong E; Reyes B; Quiñones Y; Agraz A; Herrera L
J Biotechnol; 2002 Jul; 96(3):251-8. PubMed ID: 12044553
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
9. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
Roberts PL; Walker CP; Feldman PA
Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
[TBL] [Abstract][Full Text] [Related]
10. Validation of model virus removal and inactivation capacity of an erythropoietin purification process.
Pérez M; Rodríguez E; Rodríguez M; Paez R; Ruibal I; Noa E; García O; Moya G; Martínez M; Marcelo J; Martínez A; Dubal M; Navea L; Valdés R
Biologicals; 2011 Nov; 39(6):430-7. PubMed ID: 21982851
[TBL] [Abstract][Full Text] [Related]
11. Removal of poliovirus type 1 from a protein mixture using an immunoaffinity chromatography column.
Cameron-Smith R; Harbour C
Biomed Chromatogr; 2001 Nov; 15(7):471-83. PubMed ID: 11746244
[TBL] [Abstract][Full Text] [Related]
12. Use of mep HyperCel for polishing of human serum albumin.
McCann KB; Vucica Y; Wu J; Bertolini J
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Oct; 969():241-8. PubMed ID: 25195026
[TBL] [Abstract][Full Text] [Related]
13. Large scale use of Spherosil ion exchangers in plasma fractionation.
Tayot JL; Tardy M; Gattel P; Cueille G; Liautaud J
Dev Biol Stand; 1987; 67():15-24. PubMed ID: 3038636
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
15. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
16. Chromatographic preparation and in vitro properties of albumin from human plasma.
Berglöf JH; Eriksson S; Curling JM
J Appl Biochem; 1983; 5(4-5):282-92. PubMed ID: 6679542
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
[TBL] [Abstract][Full Text] [Related]
18. Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin.
Adcock WL; MacGregor A; Davies JR; Hattarki M; Anderson DA; Goss NH
Biotechnol Appl Biochem; 1998 Aug; 28(1):85-94. PubMed ID: 9693093
[TBL] [Abstract][Full Text] [Related]
19. Chromatographic methods of fractionation.
Friesen AD
Dev Biol Stand; 1987; 67():3-13. PubMed ID: 3609484
[TBL] [Abstract][Full Text] [Related]
20. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
